Trials / Completed
CompletedNCT03058367
Benefit and Tolerability of IQP-AE-103 in Weight Loss
Double-blind, Randomised, Three-armed, Placebo-controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 108 (actual)
- Sponsor
- InQpharm Group · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study is to evaluate the benefit and tolerability of two dosages of IQP-AE-103 (990mg and 1980mg daily) in reducing body weight in overweight and moderately obese subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | IQP-AE-103 (330mg) | High dose capsules |
| DIETARY_SUPPLEMENT | IQP-AE-103 (165mg) | Low dose capsules |
| DIETARY_SUPPLEMENT | Placebo | Placebo identical to verum capsules |
Timeline
- Start date
- 2017-05-01
- Primary completion
- 2017-11-28
- Completion
- 2017-11-28
- First posted
- 2017-02-20
- Last updated
- 2018-01-03
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03058367. Inclusion in this directory is not an endorsement.